$32.02
1.274.13%
At Close: -
$32.02
00.00%
After Hours: Jul 26, 4:00 PM EDT
15 minutes delayed
Comments
Loading...
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Surgery Partners (NASDAQ:SGRY) Stock, Analyst Ratings, Price Targets, Forecasts
Surgery Partners Inc has a consensus price target of $45.69 based on the ratings of 16 analysts. The high is $73 issued by Barclays on November 30, 2021. The low is $31 issued by Macquarie on June 28, 2024. The 3 most-recent analyst ratings were released by Cantor Fitzgerald on July 10, 2024, July 9, 2024, and July 2, 2024, respectively. With an average price target of $43 between Cantor Fitzgerald, there's an implied 34.29% upside for Surgery Partners Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Cantor Fitzgerald
Macquarie
Citigroup
Benchmark
Barclays
1calculated from analyst ratings
Analyst Ratings for Surgery Partners
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/10/2024 | Buy Now | 34.29% | Cantor Fitzgerald | Sarah James | $43 → $43 | Reiterates | Overweight → Overweight | Get Alert |
| 07/09/2024 | Buy Now | 34.29% | Cantor Fitzgerald | Sarah James | $43 → $43 | Reiterates | Overweight → Overweight | Get Alert |
| 07/02/2024 | Buy Now | 34.29% | Cantor Fitzgerald | Sarah James | $43 → $43 | Reiterates | Overweight → Overweight | Get Alert |
| 06/28/2024 | Buy Now | -3.19% | Macquarie | Tao Qiu | → $31 | Initiates | → Outperform | Get Alert |
| 05/08/2024 | Buy Now | 18.68% | Citigroup | Jason Cassorla | $42 → $38 | Maintains | Buy | Get Alert |
| 05/01/2024 | Buy Now | 56.15% | Benchmark | Bill Sutherland | → $50 | Reiterates | Buy → Buy | Get Alert |
| 04/10/2024 | Buy Now | 34.29% | Cantor Fitzgerald | Sarah James | → $43 | Reiterates | Overweight → Overweight | Get Alert |
| 03/06/2024 | Buy Now | 9.31% | Barclays | Andrew Mok | → $35 | Initiates | → Equal-Weight | Get Alert |
| 03/05/2024 | Buy Now | 34.29% | Cantor Fitzgerald | Sarah James | → $43 | Reiterates | Overweight → Overweight | Get Alert |
| 02/29/2024 | Buy Now | 53.03% | RBC Capital | Ben Hendrix | → $49 | Reiterates | Outperform → Outperform | Get Alert |
| 02/27/2024 | Buy Now | 31.17% | Citigroup | Jason Cassorla | $43 → $42 | Maintains | Buy | Get Alert |
| 02/27/2024 | Buy Now | 34.29% | Cantor Fitzgerald | Sarah James | $43 → $43 | Maintains | Overweight | Get Alert |
| 11/14/2023 | Buy Now | 9.31% | TD Cowen | Gary Taylor | $39 → $35 | Upgrade | Market Perform → Outperform | Get Alert |
| 10/12/2023 | Buy Now | 56.15% | Benchmark | Bill Sutherland | → $50 | Reiterates | Buy → Buy | Get Alert |
| 09/14/2023 | Buy Now | 34.29% | Cantor Fitzgerald | Sarah James | → $43 | Reiterates | Overweight → Overweight | Get Alert |
| 08/02/2023 | Buy Now | 56.15% | Benchmark | Bill Sutherland | → $50 | Reiterates | Buy → Buy | Get Alert |
| 08/02/2023 | Buy Now | 59.28% | Barclays | Marc Solecitto | $56 → $51 | Maintains | Overweight | Get Alert |
| 07/31/2023 | Buy Now | 56.15% | Benchmark | Bill Sutherland | → $50 | Reiterates | Buy → Buy | Get Alert |
| 07/11/2023 | Buy Now | 56.15% | Mizuho | Ann Hynes | $48 → $50 | Maintains | Buy | Get Alert |
| 06/02/2023 | Buy Now | 40.54% | B of A Securities | Kevin Fischbeck | $42 → $45 | Upgrade | Neutral → Buy | Get Alert |
| 05/12/2023 | Buy Now | 49.91% | Mizuho | Ann Hynes | → $48 | Initiates | → Buy | Get Alert |
| 05/02/2023 | Buy Now | 46.78% | RBC Capital | Ben Hendrix | → $47 | Reiterates | → Outperform | Get Alert |
| 05/02/2023 | Buy Now | 56.15% | Benchmark | Bill Sutherland | → $50 | Reiterates | → Buy | Get Alert |
| 05/02/2023 | Buy Now | 46.78% | Citigroup | Jason Cassorla | $40 → $47 | Maintains | Buy | Get Alert |
| 04/21/2023 | Buy Now | 34.29% | Cantor Fitzgerald | Sarah James | → $43 | Initiates | → Overweight | Get Alert |
| 03/06/2023 | Buy Now | 46.78% | Benchmark | Bill Sutherland | → $47 | Reiterates | → Buy | Get Alert |
| 03/02/2023 | Buy Now | 24.92% | JP Morgan | Lisa Gill | $45 → $40 | Maintains | Neutral | Get Alert |
| 01/18/2023 | Buy Now | 74.89% | Barclays | Marc Solecitto | $69 → $56 | Maintains | Overweight | Get Alert |
| 12/05/2022 | Buy Now | 46.78% | Benchmark | Bill Sutherland | $60 → $47 | Maintains | Buy | Get Alert |
| 11/23/2022 | Buy Now | 49.91% | RBC Capital | Ben Hendrix | $58 → $48 | Maintains | Outperform | Get Alert |
| 11/22/2022 | Buy Now | 24.92% | SVB Leerink | Whit Mayo | $55 → $40 | Maintains | Outperform | Get Alert |
| 11/10/2022 | Buy Now | 81.14% | RBC Capital | Ben Hendrix | $62 → $58 | Maintains | Outperform | Get Alert |
| 11/10/2022 | Buy Now | 71.77% | SVB Leerink | Whit Mayo | $57 → $55 | Maintains | Outperform | Get Alert |
| 11/09/2022 | Buy Now | 18.68% | Citigroup | Jason Cassorla | $49 → $38 | Maintains | Buy | Get Alert |
| 08/03/2022 | Buy Now | 93.63% | RBC Capital | Ben Hendrix | $65 → $62 | Maintains | Outperform | Get Alert |
| 06/15/2022 | Buy Now | 12.43% | B of A Securities | Kevin Fischbeck | → $36 | Downgrade | Buy → Neutral | Get Alert |
| 05/04/2022 | Buy Now | 99.88% | Citigroup | Jason Cassorla | $61 → $64 | Maintains | Buy | Get Alert |
| 03/02/2022 | Buy Now | 71.77% | JP Morgan | Lisa Gill | $50 → $55 | Maintains | Neutral | Get Alert |
| 03/02/2022 | Buy Now | 103% | SVB Leerink | Whit Mayo | $63 → $65 | Maintains | Outperform | Get Alert |
| 03/01/2022 | Buy Now | 103% | RBC Capital | Ben Hendrix | $70 → $65 | Maintains | Outperform | Get Alert |
| 01/26/2022 | Buy Now | 96.75% | SVB Leerink | Whit Mayo | $61 → $63 | Maintains | Outperform | Get Alert |
| 12/03/2021 | Buy Now | 90.51% | SVB Leerink | Whit Mayo | — | Maintains | Outperform | Get Alert |
| 11/30/2021 | Buy Now | 127.98% | Barclays | Sarah James | — | Initiates | → Overweight | Get Alert |
| 11/29/2021 | Buy Now | 59.28% | Stifel | Tao Qiu | — | Upgrade | Hold → Buy | Get Alert |
| 11/03/2021 | Buy Now | 62.4% | SVB Leerink | Whit Mayo | — | Maintains | Outperform | Get Alert |
| 11/01/2021 | Buy Now | 56.15% | JP Morgan | — | — | Initiates | → Neutral | Get Alert |
| 10/18/2021 | Buy Now | 56.15% | SVB Leerink | Whit Mayo | — | Initiates | → Outperform | Get Alert |
| 09/10/2021 | Buy Now | 56.15% | Cowen & Co. | Gary Taylor | — | Initiates | → Market Perform | Get Alert |
FAQ
What is the target price for Surgery Partners (SGRY) stock?
The latest price target for Surgery Partners (NASDAQ:SGRY) was reported by Cantor Fitzgerald on July 10, 2024. The analyst firm set a price target for $43.00 expecting SGRY to rise to within 12 months (a possible 34.29% upside). 18 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Surgery Partners (SGRY)?
The latest analyst rating for Surgery Partners (NASDAQ:SGRY) was provided by Cantor Fitzgerald, and Surgery Partners reiterated their overweight rating.
When was the last upgrade for Surgery Partners (SGRY)?
The last upgrade for Surgery Partners Inc happened on November 14, 2023 when TD Cowen raised their price target to $35. TD Cowen previously had a market perform for Surgery Partners Inc.
When was the last downgrade for Surgery Partners (SGRY)?
The last downgrade for Surgery Partners Inc happened on June 15, 2022 when B of A Securities changed their price target from N/A to $36 for Surgery Partners Inc.
When is the next analyst rating going to be posted or updated for Surgery Partners (SGRY)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Surgery Partners, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Surgery Partners was filed on July 10, 2024 so you should expect the next rating to be made available sometime around July 10, 2025.
Is the Analyst Rating Surgery Partners (SGRY) correct?
While ratings are subjective and will change, the latest Surgery Partners (SGRY) rating was a reiterated with a price target of $43.00 to $43.00. The current price Surgery Partners (SGRY) is trading at is $32.02, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.